Welcome to our dedicated page for Dianthus Therapeutics /DE/ SEC filings (Ticker: DNTH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Dianthus Therapeutics /DE/'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Dianthus Therapeutics /DE/'s regulatory disclosures and financial reporting.
Dianthus Therapeutics ownership update: This Amendment No. 3 to a Schedule 13G/A states that Octagon-related reporting persons collectively beneficially own 1,946,667 shares of Dianthus Therapeutics common stock, equal to 3.6% of the class based on 54,448,771 shares outstanding as of March 30, 2026. The filing attributes shared voting and dispositive power over those shares to Octagon and identifies Octagon and affiliated funds as holders.
Dianthus Therapeutics director Paula Soteropoulos reported an exercise-and-sale of 599 shares of common stock. She exercised stock options to acquire 599 shares at $8.44 per share, then sold 599 shares in the open market at $85.47 per share on May 8, 2026.
The stock option related to 599 underlying shares and had an expiration date of June 6, 2032. A footnote states the transaction was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on December 23, 2025, indicating it was scheduled in advance rather than timed discretionarily.
Dianthus Therapeutics reports a wider Q1 2026 loss alongside a transformative equity raise that greatly strengthens its balance sheet. The company posted a net loss of $40.8M, versus $29.5M a year earlier, as it increased research and development spending to $34.5M and general and administrative costs to $12.5M.
License revenue was modest at $0.5M, so operations remain largely funded by external capital. In March 2026, Dianthus completed a public offering of common stock and pre-funded warrants with gross proceeds of about $719.0M, and also raised $58.7M through an at-the-market program.
These financings drove cash, cash equivalents and short-term investments to approximately $1.11B, with total assets of $1.25B as of March 31, 2026. Management states existing cash, cash equivalents and investments are expected to fund obligations for at least twelve months beyond the financial statement issuance date.
Dianthus Therapeutics reported a Q1 2026 net loss of $40.8 million, or $0.85 per share, as it increased investment in its autoimmune disease pipeline. License revenue was $0.5 million, while higher research and administrative costs continued to drive operating losses.
The company ended the quarter with approximately $1.2 billion in cash, cash equivalents and investments, supported by an upsized underwritten offering that generated about $719 million in gross proceeds, which it expects to fund operations into 2030. Management highlighted an early GO decision in the CAPTIVATE CIDP trial, Orphan Drug Designation for claseprubart in Myasthenia Gravis, and progress on the gMG Phase 3 program, the MMN Phase 2 trial, and the DNTH212 Phase 1 study and planned rheumatology indications.
BlackRock, Inc. reports beneficial ownership of 2,634,004 shares of Dianthus Therapeutics Common Stock, representing 5.1% of the class. The filing shows sole voting power for 2,582,959 shares and sole dispositive power for 2,634,004 shares as stated on the cover.
The filing identifies the holdings as held by certain Reporting Business Units of BlackRock, Inc. and is signed by a Managing Director on 04/27/2026.
Dianthus Therapeutics EVP, CFO & CBO Ryan Savitz exercised stock options and sold the resulting shares. He exercised options for 8,224 shares of common stock at an exercise price of $17.88 per share, then sold 8,224 shares of common stock at a weighted average price of $89.84 per share.
The filing shows 71,776 stock options remaining following the derivative transaction and 0 shares of common stock held directly after the sale. The transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on December 30, 2025.
Ryan Savitz submitted a Form 144 notice to sell 8,224 shares of Common Stock pursuant to an exercise of stock options dated 04/09/2026, with a cash amount shown as $719,435.52. The filing also records prior 10b5-1 sales of 114,367 shares on 03/31/2026 for $9,492,532.35.
Dianthus Therapeutics, Inc. is calling a virtual 2026 annual stockholders meeting on May 21, 2026 at 9:00 a.m. Eastern Time. Holders of 54,448,771 common shares of record on March 30, 2026 may vote online after registering at the meeting website.
Stockholders will elect three Class II directors to serve until 2029, cast an advisory vote on executive compensation, and ratify Deloitte & Touche LLP as independent auditor for 2026. The proxy details a staggered, largely independent board, committee structures, director pay in cash and stock options, and performance-based executive pay tied to drug development milestones and a reported 649% total stockholder return since the 2023 reverse merger.
Dianthus Therapeutics EVP, CFO & CBO Ryan Savitz exercised stock options and sold the resulting shares. On March 31, 2026, he exercised options to acquire 114,367 shares of common stock, including 74,367 shares at an exercise price of $8.44 and 40,000 shares at $17.88 per share. He then sold 114,367 shares of common stock in a series of open-market transactions at weighted average prices ranging from about $78.33 to $85.54 per share, under a Rule 10b5-1 trading plan adopted on December 30, 2025. Following these transactions, the filing shows he directly owns no shares of common stock.